This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why is Novo Nordisk Stock Up More Than 50% in Past Year?
by Zacks Equity Research
We take a look at the factors that led to the rise in Novo Nordisk's (NVO) share price in the past year.
Boston Scientific Rises 8.3% on Upbeat 4Q Preliminary Sales
by Zacks Equity Research
Boston Scientific (BSX) pulls out all the stops to strengthen its core business as well as invest more in the global markets. This also gets reflected in its preliminary sales results.
Masimo Gets FDA Nod for Rad-97, Enables Healthcare at Home
by Zacks Equity Research
Masimo (MASI) states that with its inherent touchscreen interface, Rad-97 is user-friendly for clinicians and non-clinicians and can be easily tailored to cater to the needs of home users.
Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up
by Zacks Equity Research
Adamas (ADMS) shares climb on the commercial launch of Gocovri in the United States for treating dyskinesia in patients with Parkinson's disease. This is the first FDA approved drug for the ailment.
Emergent Down on '18 View, Posts Preliminary '17 Results
by Zacks Equity Research
Emergent (EBS) provides preliminary results for 2017 and its guidance for 2018. The results exceed management's outlook issued in November last year.
Acorda's Shares Down on Disappointing Ampyra View for 2018
by Zacks Equity Research
Acorda (ACOR) announces preliminary sales numbers of its key multiple sclerosis drug, Ampyra, for Q4. The company's net sales expectations are higher year over year.
Novo Nordisk Confirms Bid for Ablynx But Faces Rejection
by Zacks Equity Research
Novo Nordisk (NVO) confirmed its revised offer made on Dec 22, to acquire Ablynx NV for $3.1 billion.
Agenus Inc., (AGEN) Jumps: Stock Rises 11.4%
by Zacks Equity Research
Agenus Inc. (AGEN) was a big mover last session, as the company saw its shares more than 11% on the day amid huge volumes.
Alnylam, Sanofi Announce Restructuring Deal for RNAi Products
by Zacks Equity Research
Alnylam (ALNY) and Sanofi entered into a strategic restructuring of their RNAi therapeutics rare genetic diseases alliance.
The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines
Exelixis Amends Cabozantinib-Tecentriq Phase Ib Trial
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced an amendment to the protocol for the phase Ib trial of cabozantinib combined with Tecentriq whereby there will be four new expansion cohorts to the trial.
Cancer Space Update: New Regulatory Status for 3 Major Drugs
by Zacks Equity Research
Merck's Keytruda receives approval in Japan for bladder cancer. Seattle Genetics' Adcetris and Novartis' Kisqali get regulatory status updates from the FDA.
Emergent Starts Phase II Study on Anti-influenza Candidate
by Zacks Equity Research
Emergent (EBS) initiates a phase II dose-ranging trial to evaluate the safety, pharmacokinetics and clinical benefit of its investigational FLU-IGIV to treat influenza virus infection.
United Therapeutics (UTHR) Collaborates With Corsair Pharma
by Zacks Equity Research
United Therapeutics (UTHR) entered into an exclusive license agreement with Corsair Pharma.
Pfizer (PFE) Collaborates With Sangamo for Gene Therapy
by Zacks Equity Research
Pfizer entered into collaboration agreements with Sangamo Therapeutics and private biotech, Arvinas.
Inovio Amends Chinese Deal for Immunotherapy, Shares Up
by Zacks Equity Research
Inovio (INO) entered into an amended agreement with ApolloBio Corporation and grants ApolloBio the exclusive right to develop and commercialize VGX-3100 within Greater China.
Valeant (VRX) to Settle Allergan Litigation for $290 Million
by Zacks Equity Research
Valeant (VRX) and Pershing Square decided to resolve the claims of the long standing Allergan lawsuit for $290 million. Valeant will now pay 33% of the costs, down from the previous agreement of 60%.
Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018?
by Zacks Equity Research
Exelixis (EXEL) had a phenomenal run in 2017 driven by sales of Cabometyx and we expect the momentum to continue in 2018 on the back of the label expansion of the drug.
Exelixis' Cabometyx Gets FDA Nod for First-Line Kidney Cancer
by Zacks Equity Research
Exelixis (EXEL) received a significant boost with the approval of label expansion of lead drug Cabometyx for first-line kidney cancer.
Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak
by Zacks Equity Research
Endo (ENDP) announced better-than-expected results for the third quarter. However, weakness in the generics segment persist and will impact results.
Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up
by Zacks Equity Research
Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The company ups its guidance, courtesy of a continued positive execution across all business segments.
Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up
by Zacks Equity Research
Merrimack (MACK) reported narrower-than-expected loss in the third quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.
Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates
by Zacks Equity Research
Pacira's (PCRX) earnings surpassed estimates but sales missed the same in the third quarter of 2017. The company remains focused on the label expansion of Exparel.
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Catalyst Pharma (CPRX) remains focused on the development of its pipeline candidate firdapse in the third quarter of 2017.
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down
by Zacks Equity Research
VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.